Mirati Therapeutics Inc. closed an underwritten public offering of 3,162,500 common shares priced $38.85 each.
The San Diego-based cancer drug developer raised about $139.2 million through the offering.
Underwriters exercised their option to buy 412,500 common shares. Certain investor bought pre-funded warrants to buy 421,650 common shares, in lieu of stock.
Cowen, Barclays and SunTrust Robinson Humphrey acted as joint book-running managers for the offering, with Oppenheimer & Co. as lead manager and H.C. Wainwright & Co. as co-manager.
